[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liposomal-amphotericin-b\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liposomal-amphotericin-b":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100574065","phase-4-population-pharmacokinetics-of-l-amb-in-chinese-patients-assisted-by-extracorporeal-membrane-pulmonary-oxygenation-ecmo-100574065",false,"NCT06754436","Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)","Inclusion Criteria:\n\n* Diagnostic criteria for invasive fungal infections presenting to the intensive care unit (ICU) with probable or proved patients According to the 2021 EORTC\u002FMSGERC guideline.\n* Requiring ECOM assistance.\n* Age 18 years.\n\nExclusion Criteria:\n\n* Intolerance of L-AmB therapy.\n* Pregnancy.\n* Expected survival time \\\u003C24 hours.\n* Lack of necessary data on patient demographics physiopathology, and clinical status.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The goal of this study is to investigate the effects of ECMO-assisted therapy on L-AmB PK parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of L-AmB in the ECMO population. To establish and validate a population pharmacokinetic model for liposomal amphotericin B in patients with critically ill patients of invasive fungal infections treated with ECMO adjuvant therapy, and to explore the pharmacokinetics\u002Fpharmacodynamics of the drug with different dosing regimens.",[25,26],"Invasive Fungal Infections","Liposomal Amphotericin B","NOT_YET_RECRUITING","2024-12-30",{"date":30,"type":31},"2024-12-31","ACTUAL",{"date":33,"type":19},"2025-01-10",{"date":35,"type":19},"2026-02-01",{"name":37,"class":38},"Beijing Anzhen Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100326406","pharmacokinetics-of-liposomal-amphotericin-b-in-critically-ill-vs-non-critically-ill-hematological-patients-exploration-of-covariates-100326406","NCT03529617","Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates","Inclusion Criteria:\n\n* Treatment with L-AmB\n* Admitted to an ICU or Hematology ward\n\nExclusion Criteria:\n\n* DNR 2 or 3\n* Pregnant or lactating women\n* Previous documentation of intolerance\u002Fsensitivity to L-AmB",{"count":47,"type":19},60,"1 Month","OBSERVATIONAL","This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.",[52,26,53],"Pharmacokinetics","Critically Ill Patients","RECRUITING","2024-07-02",{"date":57,"type":31},"2024-07-03",{"date":59,"type":31},"2016-10-19",{"date":61,"type":19},"2025-12-31",{"name":63,"class":38},"Universitaire Ziekenhuizen KU Leuven"]